LINDITA VINCA: Open Payments
NPI 1396093993 · CHESHIRE, CT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$196,673 in 419 payments from 24 companies in 2025. Trend: 2023 $73,348 · 2024 $143,168 · 2025 $196,673
Speaker / faculty: $128,018Travel & lodging: $36,176Consulting: $11,984Honoraria: $10,850Food & beverage: $9,645
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 103 | $108,107 |
| GENZYME CORPORATION | 39 | $22,315 |
| Organon LLC | 35 | $14,996 |
| Incyte Corporation | 36 | $13,332 |
| Regeneron Healthcare Solutions, Inc. | 32 | $13,149 |
| ABBVIE INC. | 45 | $10,755 |
| Galderma Laboratories, L.P. | 22 | $6,370 |
| Arcutis Biotherapeutics, Inc. | 20 | $5,418 |
| Medimetriks Pharmaceuticals, Inc. | 2 | $488 |
| UCB, Inc. | 20 | $394 |
Products named: TREMFYA, DUPIXENT, VTAMA, SKYRIZI, Zoryve, OPZELURA, Clindacin ETZ, Bimzelx.
Industry payments across CT — which companies pay providers there.
